

# Mota Ventures

12:14 28 Jan 2020

## Buds & Duds: Marijuana stocks find their footing; Mota jumps on genetic library deal

Cannabis stocks recovered some territory on Tuesday in the wake of one of Wall Street's worst Mondays in a while.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, ticked up 2% to 114 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF rose 3% to C\$9.07, while the OTCQX Cannabis index climbed 2.6% to 463.5 points.

### Buds

Mota Ventures Corp (CSE:MOTA) (OTCMKTS:PEMTF) shares traded higher after the company signed a licensing and royalty agreement with Phenome One Corporation, a private genetic and seed preservation company with over 350 cultivars and access to around 1,700 unique genetics in its seed bank.

Under the terms of the deal, Mota has the right to propagate, cultivate, harvest and process at least 10 selected cultivars from Phenome's genetic library — the largest such library in Canada — and to sell anything it produces from the selections.

Its shares were trading at C\$0.52 in Canada and US\$0.40 over the counter on Tuesday morning.

Canopy Growth Corporation (NYSE:CGC) got a boost from analysts at BMO Capital Markets. Tany Chen upgraded the firm's rating of Canopy to Outperform from Market Perform, according to a report from Barron's.

Chen also raised the company's price target to C\$40 from C\$25.

"We believe the stock at current levels offers a better relative return profile considering that a number of other LPs with value-priced brands will likely continue to be at risk of requiring additional financings," Chen wrote.

Canopy shares gained 6.4% to C\$30.20 on Bay Street and 6.2% to US\$22.89 on Wall Street.

### Duds

On the other side of the coin, Hexo Corp (NYSE:HEXO) (TSE:HEXO) lost ground following a downgrade from MKM Partners.


The firm bumped Hexo down to Neutral from Buy after it was sued for breach of contract by MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF), according to a MarketWatch report.

MediPharm says the pot producer failed to pay for millions of dollars' worth of cannabis oil over a supply deal signed last year.

**Price:** 0.36

**Market Cap:** \$29.07 m

### 1 Year Share Price Graph



May 2019 February 2020 May 2020

### Share Information

**Code:** MOTA

**Listing:** CSE

**52 week High Low**  
0.82 0.08

**Sector:** Cannabis

**Website:**

### Company Synopsis:

*Mota Ventures Corp. is an established e-commerce, direct-to-consumer provider of a wide range of CBD products in the US and Europe. Sales channels in the US carry the First Class CBD line, featuring a CBD hemp-oil formulation derived from hemp grown and cultivated in the United States.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

"The hairy just got hairier," analyst Bill Kirk wrote. "... [this lawsuit is] the straw that has broken our back."

MediPharm is suing Hexo for C\$9.8 million related to unpaid shipments of marijuana, the MarketWatch report said.

Hexo stock dropped 1.5% to C\$1.73 in Toronto and 1.5% to US\$1.31 in New York.

MediPharm, however, jumped 7.6% in the morning in Canada and 7.1% over the counter.

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter @andrew\_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Mota Ventures named herein, including the promotion by the Company of Mota Ventures in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).